Lapatinib

epidermal growth factor receptor ; Mus musculus







23 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 33766630 Lapatinib alleviates TOCP-induced axonal damage in the spinal cord of mouse. 2021 May 15 3
2 32490320 Loss of c-Jun N-terminal Kinase 1 and 2 Function in Liver Epithelial Cells Triggers Biliary Hyperproliferation Resembling Cholangiocarcinoma. 2020 Jun 2
3 32582968 Lapatinib‑induced inhibition of ovarian function is counteracted by the STAT3 pathway both in vivo and in vitro. 2020 Sep 2
4 33176309 Lapatinib Decreases the Preimplantation Aneuploidy Rate of in vitro Fertilized Mouse Embryos without Affecting Completion of Preimplantation Development. 2020 1
5 30719209 Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility. 2019 Jan 4 2
6 30125265 Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo. 2018 Aug 20 6
7 28061785 Short-term early exposure to lapatinib confers lifelong protection from mammary tumor development in MMTV-erbB-2 transgenic mice. 2017 Jan 6 2
8 26692570 Bidirectional cross-regulation between ErbB2 and β-adrenergic signalling pathways. 2016 Mar 1 1
9 25375038 ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice. 2015 Jan 3
10 25700543 The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer. 2015 Apr 30 1
11 26581390 Upregulation of EGFR signaling is correlated with tumor stroma remodeling and tumor recurrence in FGFR1-driven breast cancer. 2015 Nov 18 6
12 24279293 EGFR inhibitors erlotinib and lapatinib ameliorate epidermal blistering in pemphigus vulgaris in a non-linear, V-shaped relationship. 2014 Jan 2
13 25249538 Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. 2014 Sep 30 2
14 23913859 Profibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases. 2013 Nov 1
15 22011930 Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. 2012 Mar 1
16 22912742 Cardiac-specific over-expression of epidermal growth factor receptor 2 (ErbB2) induces pro-survival pathways and hypertrophic cardiomyopathy in mice. 2012 1
17 21685235 Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial. 2011 Aug 2
18 20459769 Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. 2010 May 11 3
19 20735208 Rational approach to the synthesis, evaluation, and (68)ga labeling of a novel 4-anilinoquinoline epidermal growth factor receptor inhibitor as a new imaging agent that selectively targets the epidermal growth factor receptor tyrosine kinase. 2010 Aug 2
20 19141783 Effect of lapatinib on the development of estrogen receptor-negative mammary tumors in mice. 2009 Jan 21 2
21 19536776 The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38. 2009 Dec 15 3
22 19554571 Initial testing (stage 1) of lapatinib by the pediatric preclinical testing program. 2009 Oct 3
23 18664652 Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. 2008 Aug 6 3